Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if, in mid- to late pubertal girls with
hyperandrogenism (HA), androgen-receptor blockade (spironolactone) alone normalizes
sleep-wake luteinizing hormone (LH) pulse frequency (primary endpoint) and overall LH and
follicle-stimulating hormone secretion (secondary endpoints).
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Virginia
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)